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Abstract 
 
Magnetorheological (MR) fluids are suspensions of magnet iron microparticles known 
as carbonyl iron (CI). MR fluids have the ability to increase in viscosity and display high yield 
stress with the application of an external magnetic field. Herein we explore the feasibility of 
using these materials to influence the crystallisations of active pharmaceutical ingredients in 
an attempt to affect crystal morphology. Within the context of this study we developed a range 
of magnetorheological fluids by modifying carbonyl iron (CI) particle surfaces with a series of 
ligands. We used acid terminated PEG, oleic acid, carminic acid and 1-naphthaleneacetic acid 
as the functionalising ligands. We demonstrated control over crystal morphology in 
carbamazepine (CBZ) with the use of MR fluids. We managed to selectively crystallise form 
II of CBZ in PEG and carminic acid functionalised CI, and form III (commercially 
available/active form) with oleic acid and 1-naphthaleneacetic acid functionalities. 
The second part of this study was concerned with improving the heat generation 
efficiency of iron oxide nanoparticles (NPs) for thermotherapy. Iron oxide NPs can generate 
heat loss through interaction with an alternating magnetic field (AMF). It was shown in the 
literature that a “tight” clustering of nanoparticle clusters can be used to increase heat 
generation efficiency. We therefore investigated the effect of coupling a temperature sensitive 
polymer (with a LCST of 32 ˚C), poly-N-isopropyl acrylamide (PNIPAM), to a “tight” 
clustering of magnetic iron oxide nanoparticles. The aim was that this coupling could produce 
a temperature induced aggregation of the NP clusters, concentrating them and therefore 
increasing the total heating power. Unfortunately, modification of PNIPAM for coupling 
resulted in an unknown product that failed to exhibit the desired properties.   
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Chapter 1. Introduction 
1.1 Magnetic Micromaterials. Magnetorheological (MR) materials are fluids 
composed of soft magnetic particles dispersed in a non-magnetic fluid medium. The properties 
of these fluids can switch between a fluid-like state and a solid-like state in milliseconds by 
controlling the strength of an applied magnetic field [1]. The properties of MR fluids are a 
result of induced dipoles leading the particles to form chain-like structures parallel to the 
direction of the applied magnetic field [2]. The magnetic particles are also applied to materials 
such as elastomers and foams to induce an MR effect and realise a wide range of flow and 
shear properties [3]. The variable rheological properties of MR fluids have found widespread 
use in industry, where their discovery stemmed from an extensive research programme to 
overcome the speed limitations of computers in 1948 [4]. Their applications now range from 
dampers such as those in braking and shock absorbing systems in vehicles, to force sensors in 
bridge bearings [5]. 
1.2 MR Fluid Composition and Properties. MR fluids contain a high concentration 
of magnetisable particles. Differences in particle size and concentration can produce 
significant differences in the behaviour of the fluid [6]. Particle sizes typically range from 0.1 
– 10 µm, and larger particles will support many hundreds of magnetic domains. This is 
important because a larger number of magnetic domains translates into maximum inter-
particle attraction and magnetorheological effect [2]. Optimising conditions for a maximum 
magnetorheological effect also means choosing a particle material with a high saturation 
magnetisation, MS [7]. In terms of pure metals, this material is iron, which has a saturation 
magnetisation of 2.21 µB [8].  
Saturation magnetisation is the property of magnetic materials that determines the 
maximum amount of magnetisation the material can hold. It is the point at which any 
increases in magnetic field cannot affect the magnetisation of the material. Magnetisation, M 
is related to magnetic induction or magnetic flux density, B, expressed by the following 
relationship: 
 𝐵 = µ!(𝐻 +𝑀) 
 
(1) 
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Where µ0 is the permeability of free space and H is the induced magnetic field. The 
magnetic response of these materials also varies linearly with the applied magnetic field, H, 
and this is referred to as susceptibility (dimensionless quantity),	𝜒: 
 𝜒 = 𝑀𝐻  
 
Both magnetisation and susceptibility of the magnetic material play important roles in the 
design of an MR fluid [9]. These properties lead to variations in the intensity of the 
magnetorheological effect displayed by the MR fluid. The high saturation magnetisation of 
iron is the reason why the most common magnetic material used in the preparation of MR 
fluids is pure iron. This is also referred to as carbonyl iron, because it is produced from the 
thermal decomposition of iron pentacarbonyl [10]. 
 The carrier fluid is typically chosen based on its rheological properties and temperature 
stability. Considering that many MR fluids are used in moving parts, it is important that the 
viscosity of the carrier fluid is low and independent of temperature. This is why many 
lubricants and oils are used as carrier fluids, because in the ‘off’ state their natural viscosities 
will not interfere with the workings of the mechanism [11]. 
 It is also important to note that MR fluids can often contain other additives to improve 
lubrication and reduce sedimentation of the particles in the carrier. Sedimentation is often 
controlled by the addition of thixotropic agents such as silica gels [12] and surfactants such as 
stearates and carboxylic acids [13]. However, during development and commercialisation of 
MR products, it became apparent that the high stress and high shear rates over time led to the 
thickening of the MR fluids, known as “In-Use-Thickening” (IUT). This phenomenon 
describes behaviours observed in MR fluids that have been in service for long time periods, 
where the ‘off’ state viscosity increases to a point where the fluid compromises the 
functionality of the product. The cause of IUT has been identified as a result of nano-sized 
particulates being expelled from the surface of the iron particles from shear forces, leading to 
thickening of the fluid [12].  
 1.3 Rheology Fundamentals. In its simplest form, rheology is the study of the flow 
and deformation of matter. The field-dependent chaining of particles in an MR fluid produces 
(2) 
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forces that resist deformations from shear stress without breaking, which is what gives the 
fluid its solid-like appearance [14]. Shear stress arises from resistance to a force component 
parallel to the cross-section of the material (Fig. 1.3.1) [15]. The value required to exceed the 
shear stress, leading to the breakdown of the structure, is referred to as the yield stress of the 
material. The data in Table 1.3.1 demonstrates how the yield stress of typical MR fluids 
increases as a function of magnetic field strength. 
 
 
 
 
 
 
 
 
 
Figure 1.3.1. Schematic Representation of simple shear flow. Reprinted from [2]. 
 
 
Table 1.3.1. Comparison of measured dynamic yield stresses for 40 vol% MR fluids 
containing coarse or fine powder. 
  
 Coarse CI Powder (7-9 µm) Fine CI Powder (2 µm) 
Magnetic Field Strength (G) Measured Dynamic Yield Stress (kPa) 
2000 22 ± 1 14 ± 1 
4000 45 ± 3 35 ± 1 
6000 84 ± 2 71 ± 2 
8000 124 ± 3 102 ± 2 
*Data was collected and organised from [10]. 
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We can therefore model the field dependent behaviour of MR fluids as Bingham plastics 
where the shear stress, 𝜏 is a function of the sum of the field dependent yield stress 𝜏" and the 
dynamic viscosity, 𝜂: 𝜏 = 𝜏" + 𝜂𝛾 
 
Dynamic viscosity is defined as: 𝜂 = 𝜏𝛾 
 
Where 𝛾 is the shear rate [2, 11, 14]. 
 The rheological properties of MR fluids, specifically the display of high yield stress, 
makes these materials very attractive for mechanical applications. However, their off-state 
rheological properties make the application of MR fluids to odd geometries difficult. Problems 
such as these have led to increased interest in MR foams. 
1.4 MR Foams. To keep MR fluids in the active region of a device, an absorbent 
matrix such as a sponge or open-celled foam is used as a lining containing the MR fluid. The 
fluid is thereby constrained by capillary action in the absorbent matrix [16]. As seen in the 
image below (Fig. 1.4.1) the absorbent matrix is attached to one of the poles. Applying a 
magnetic field produces a yield strength in the foam, and therefore a resistance to shear 
motion. Due to the variable shapes that the foams can adopt, MR fluid foams can be applied to 
both linear and rotary devices [2]. Furthermore, these devices are free of the sedimentation 
issues normally faced in MR fluids because of the capillary action of the matrix. This action 
allows the foams to retain the fluid even in the absence of a magnetic field.  
Reported leakages from MR devices have led to concerns around environmental 
contamination [17]. To combat these issues, MR elastomers are being investigated as 
replacements. 
1.5 MR Elastomers. MR elastomers differ from foams and fluids in that the carrier 
fluid is a polymer medium. Therefore, the application of a magnetic field results in a field 
dependent modulus, as opposed to a field-dependent yield stress. Hence, elastomers find more 
use in the application of shock absorption rather than dampening [18]. Although the 
(3) 
(4) 
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applications of elastomers are few, their ability to affect stiffness suggests the potential for use 
in devices that require variable stiffness such as vibration absorbers in propeller aircraft [19]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1.4.1 The basic elements of MR foam. Reprinted from [6]. 
 
 
1.6 Magnetic Nano Materials. The important role of nanomaterials is evidenced by 
their ubiquity in the consumer market, from beauty to healthcare products, and the broad range 
of disciplines they encompass, from agriculture to space technology [20]. The unique 
properties of these materials stem from their nanoscale (1 – 100 nm) behaviours. Of particular 
interest is the property of superparamagnetism in iron oxide nanoparticles, which is a result of 
thermal fluctuations on very small ferromagnetic clusters within the particle [21]. This 
property (described in more detail in the next section) manifests in induced magnetisation 
under an applied magnetic field and no observed magnetisation in the absence of a magnetic 
field, making them readily stable in physiological conditions [22]. Furthermore, to be 
superparamagnetic, the particles must be below a critical size. For iron, this is < 20 nm, below 
which the particles experience spontaneous magnetisation reversal and hence no net 
magnetisation in the absence of a field [23]. The small size of superparamagnetic (SPM) 
nanoparticles (NPs) and their strong magnetic response makes them attractive materials for 
biomedicine, where they can be used as magnetic probes for bio imaging and therapeutic 
 
 
19 
applications [24]. In the next section, we will concentrate on monocomponent nanomaterials 
such as iron oxide. 
1.7 Synthesis and Properties. In the past, iron oxide nanoparticles (NPs) for magnetic 
fluids were commercially manufactured by the mechanical grinding of magnetite (Fe3O4) in 
the presence of surfactants, producing large particle size distributions. Therefore, the 
pioneering synthesis of monodisperse iron oxide nanoparticles by the decomposition of iron 
pentacarbonyl in the presence of oleic acid, was well received [25]. However, the demand for 
superparamagnetic nanoparticles led research to achieve more precise size and distributions. 
These investigations into organic phase methods indicated that particle size could be tuned by 
controlling the ratio of surfactant to solvent (Fig. 1.7.1A-D) [26, 27]. Furthermore, particle 
geometries such as the octahedral Fe3O4 NPs and the Fe3O4 nanoprisms seen in Fig. 1.7.1 E 
and F were also a result of controlling surfactant concentrations. The octahedral NPs were 
formed in a 1:2 molar ratio of iron (III) oleate to oleylamine, where altering the ratios to 4:1 or 
1:1 produced irregular octhedra (Fig 1.7.1E) [28]. Nanoprisms formed as a result of an 
oleylamine surfactant and a high pressure synthetic method. This high pressure from the 
autoclave allowed oleylamine to preferentially bind to (111) facets, slowing those facet 
growths and leading to a prism-like geometry (Fig 1.7.1F) [29]. 
Although surfactant ratio can regulate competitive growth to produce specific 
morphologies, temperature control can produce other oxidation states and facilitate size 
control. Fig. 1.7.1 G-J demonstrates size and morphology control of FeO obtained by varying 
heating parameters [30]. 
The magnetic behaviour of a material can vary depending on the structure and its 
electron configuration. The relevant magnetic properties of superparamagnetic (SPM) NPs are 
described by the Néel-Arrhenius equation: 
 𝜏 = 𝜏!# $%&!'( 
 
Where ∆𝐸 is the energy barrier to the reversal of the magnetic moment, 𝑘)𝑇 is the thermal 
energy and 𝜏 is the time between magnetisation flips. Considering that ∆𝐸 is equal to the 
product of the anisotropy constant and volume of the particle, superparamagnetism is only 
(5) 
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observed in very small particle geometries. Because only at this scale is ∆𝐸 comparable to the 
thermal energy, 𝑘)𝑇 at room temperature [31, 32]. This explains why the flipping of magnetic 
moments happens spontaneously at room temperature for SPM NPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.1. (A) TEM image of 16 nm Fe3O4 NPs. Copyright 2002 American Chemical 
Society. (B−D) TEM images of (B) 7 ± 0.5 nm, (C) 8 ± 0.4 nm, and (D) 10 ± 0.8 nm Fe3O4 
NPs. The scale bars are 20 nm. Copyright 2009 American Chemical Society. (E) TEM image 
of octahedral Fe3O4 NPs. Copyright 2009 Royal Society of Chemistry. (F) TEM image of 
Fe3O4 nanoprisms. Copyright 2010 Royal Society of Chemistry. TEM images of (G) 14 nm 
spherical and (H) 32 nm and (I) 53 nm truncated octahedral FeO NPs and (J) SEM image of 
truncated octahedral FeO NPs. Figure is a reprint from [21]. 
 
Expanding this concept, we can see that inducing several flips in magnetization by applying an 
alternating magnetic field (AMF) can generate heat loss. As a result, the thermotherapy of 
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magnetic hyperthermia treatment exploits the heat generation capabilities of iron oxide 
nanoparticles. Under an AMF these particles generate a local temperature increase significant 
enough to kill cancer cells [33, 34]. The application of iron oxide nanoparticles to facilitate 
cellular level local heating is possible because magnetically induced aggregation of the 
particles can increase heat generation power, and the surfaces of the nanoparticles can easily 
be modified with a biocompatible functionality. 
1.8 Surface Modification and Targeting Ability. An attractive property of iron oxide 
nanoparticles is their high surface area to volume ratio, because it provides the opportunity for 
high loading with relevant ligands [24]. For NPs to be successful in thermotherapy they have 
to be internalised by their target with high efficiency. Cellular internalization means 
interacting with membrane-embedded receptors or the lipid-bilayer [35]. Therefore, NPs have 
to be functionalised with ligands that can bind with specificity and high affinity to receptors 
on its target. Recent work in China has shown that dopamine-modified cyclodextrin 
nanoparticles display superior intracellular internalisation [36]. Unfortunately, these catechol 
moieties also show a high affinity for iron oxide, binding irreversibly, and hence cannot be 
expressed on iron oxide NP surfaces. However, the affinity of catechol moieties, like 
nitrodopamine, to iron oxide provides the opportunity of converting these into anchors for 
facile functionalisation of iron oxide NP surfaces [37].  
Nitrocatechols can be easily coupled to an acid-terminated polymer via an amidation 
reaction. This process allows for seemingly endless modification of iron oxide NP surfaces. 
Reimhult et al. used this method to modify iron oxide NPs with a temperature sensitive 
polymer that could allow for temperature induced aggregation of NPs (Fig. 1.8.1) [38].  
Improving the efficacy of iron oxide NPs in nanomedicine has led to several 
developments. Among these are the encapsulating of pharmaceuticals in NP polymer brushes 
for intracellular delivery, and the incorporation of iron oxide NPs into lipid membrane vesicles 
for a NP triggered release of pharmaceuticals [39, 40]. The lipid membrane vesicles can allow 
for both hydrophobic and hydrophilic pharmaceuticals to be incorporated as the vesicles 
contain an aqueous interior and an amphiphilic membrane (Fig. 1.8.2). Both of these 
developments exploit the magnetic properties of iron oxide nanoparticles by using AMF 
induced heating to soften the polymer brushes releasing the encapsulated drug. 
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Figure 1.8.1. 10.7 nm/PNIPAM 20 kDa, 5 mg/mL in a poly(methyl methacrylate) (PMMA) 
cuvette placed upon a neodymium magnet, (A) at room temperature, (B) at 40 °C. In plastic 
cuvettes, a discoloration of the cuvette wall remains, interpreted as a high affinity of the 
dehydrated PNIPAM for the cuvette walls. Reprint from [38]. 
 
 
 
 
 
 
 
Figure 1.8.2. Schematic Representation of (a) liposomes containing iron oxide NPs in their 
bilayer (reprint from [41]) and (b) clustered iron oxide NPs encapsulating DOX in its polymer 
functionality (reprint from [39]). 
 
 
(a) (b) 
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1.9 Conclusion. The importance of iron in the micro and nano world is due its unique 
magnetic properties. Magnetic microparticles exhibit ferromagnetism that allows for the 
manipulation of the rheological properties of a fluid in response to a magnetic field. Their 
behaviour under an applied magnetic field forms networks of confined microenvironments as 
a result of a chain-like self-assembly. This response has found many uses in industry, 
especially in shock absorbers and dampers. In contrast, magnetic nanomaterials display 
superparamagnetism, a property that allows for magnetically induced heating. This property, 
along with their small size and relatively easy surface modification makes these materials 
excellent tools in nanomedicine. 
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Research Objectives. Our study contains two primary objectives:  
1. To develop magnetorheological fluids as smart media for controlling crystallisations. 
In order to achieve this goal, we have set out the following objectives: 
a. Develop a range of MR fluids by modifying the surface of iron micro particles 
with stabilising ligands. The goal is that these ligands aid in deterring the 
sedimentation rate of the particles and provide a means of interacting with drug 
molecules. 
b. Investigate the crystallisation of an active pharmaceutical ingredient (API) with 
emphasis on the effect of MR fluid on crystal morphology. 
c. Determine if different solvent systems can be used in the development of MR 
crystallisation media. 
2. To synthesise and modify iron oxide nanoparticle clusters with a temperature sensitive 
polymer, poly-N-isopropyl acrylamide (PNIPAM), for improving heating efficiencies 
in thermotherapy. To achieve this, we set the following objectives: 
a. Synthesise and stabilise iron oxide nanoparticle clusters by reproducing the 
method published by Hayashi et al. [39]. 
b. Synthesise and characterise PNIPAM. 
c. Modify iron oxide nanoparticle clusters with PNIPAM polymer. 
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Chapter 2. Magnetorheological Fluids for Controlling Pharmaceutical Crystal Growth 
2.1.1 Crystallisation and Polymorphism. Solution crystallisation is one of the most 
widely used methods for the manufacturing of active pharmaceutical ingredients (APIs) [43]. 
It is an attractive method because a single process combines both particle formation and 
purification. The complex process of crystallisation is very sensitive to environmental 
conditions and hence we often obtain more than one form of an API known as polymorphism. 
In an ideal case, we want to obtain a pharmaceutical with a specific size, crystal habit, crystal 
structure and low degree of imperfection. Considering that the spontaneous appearance of a 
new phase occurs in a system that is in non-equilibrium, the crystallisation process first begins 
with the formation of a supersaturated solution. Then, the dissolved molecules can begin to 
aggregate, leading to fluctuations in the bulk concentration, eventually forming nuclei. The 
nuclei begin to grow as particles diffuse to the surface of existing nuclei (Fig. 2.1.1) [44]. 
 
 
 
 
 
 
 
 
Figure 2.1.1. Schematic Representation of the pathway leading from solution to solid showing 
(a) supersaturated solution, (b) ordered subcritical cluster of solute molecules, (c) ordered 
crystalline nuclei, and (d) solid crystal. Image and caption are a reprint from [44]. 
 
Polymorphism describes the variation in solid form that an active pharmaceutical 
ingredient (API) can take. This plays an important role in defining the stability and drug 
release properties of an API because crystalline variations such as polymorphism are 
responsible for differences in bio-inequivalence and chemical and physical stability [45]. In 
fact, these variations have increased interest in polymorphism, crystallisation and process 
development in the pharmaceutical industry [46].  
(a) 
(b) 
(c) (d) 
 
 
27 
Ostwald’s step rule states that in general, the least stable (less soluble) polymorph 
crystallises first. This is because the state which is sought out is the nearest in stability to the 
original, instead of the more thermodynamically stable one [47]. Although this rule is not a 
universal law, it is a possible preferred tendency. This behaviour is the source of much trouble 
in industry as the more thermodynamically stable polymorphs tend to form during storage of a 
pharmaceutical, i.e. on the shelves [48]. In the summer of 1998 the protease inhibitor ritonavir 
was removed from the market because the storage of the API led to the formation of a much 
less soluble crystal form II, which greatly reduced oral bioavailability (Fig. 2.1.2) [49]. 
Similarly, in 2008 the dopamine agonist rotigotine (Neupro) was recalled because of the 
appearance of a new, less soluble polymorph [50]. Hence the topic of controlling the 
polymorphism of pharmaceutical ingredients has attracted increasing attention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.2. Hydrogen bonding network for Ritonavir (a) form I and (b) form II. Reprint from 
[49]. 
(a) (b) 
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In an effort to address the shortfalls of solution crystallisation in controlling 
polymorphism, pharmaceutical industries are moving towards the addition of guest molecules 
such as salt-formers, co-formers and solvates. These work by pairing a drug with a counterion 
to create a salt version of the drug, a process that creates new chemical entities and widens the 
selection basis without altering the drug [51, 52]. However, these methods would require 
extensive testing in order to determine a suitable guest molecule, making these methods 
expensive and time consuming [53]. It is known that the physical characteristics of a crystal 
can be improved in a crystallisation media that promotes the suppression of convection 
currents, sedimentation and nucleation rates. A medium like this can be realised in a viscous 
gel environment. The technique of growing crystals in gels was first reported in the work of 
Raphael Eduard Leisegang who, in 1896, observed patterns arising from the periodic 
precipitation of a weakly soluble salt in a hydrogel [54]. 
2.1.2 Crystal Engineering in Confined Spaces. For a long time, a very wide range of 
materials had been recognised to form gels. It wasn’t until the late 1990’s however, that ureas, 
amides, porphyrin derivatives and many others, were discovered to form fibrous gels. The 
assembly of these low molecular weight compounds (known as low molecular weight gelators, 
LMWG), into fibrous gel networks offers the potential to tune gelators to specific conditions 
[55], i.e. solvent systems or crystal substrates. LMWGs can be synthesised to match the 
chemistry of an API, and hence provide an active nucleation surface [56].  
In 2010, Steed et al. crystallised a range of drug substances in organic LMWGs, referred to 
as organogels [57]. The procedure involved the warming of the gelator and drug in a 
compatible solvent system and allowing the mixture to cool. The crystallisation of 
carbamazepine (CBZ) in these organogels produced significantly larger crystals, up to 30 
times larger in toluene gels, however, the crystal habits observed in these gels were the same 
as those in their corresponding reference (i.e no gel). Adjusting the ratios of co-solvent to 
toluene and varying the CBZ concentrations resulted in a preference for one form over 
another. More importantly, the lack of gelator-drug co-crystal formations indicated a phase 
separation between gel and crystals. It is possible that the microenvironment afforded by these 
LMWGs was small enough to restrict the mobility of solute molecules, but not to force 
interactions between solute molecules and the gel network chemical structure. 
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A study performed on crystallisations of CBZ in polymer microgels suggests that the 
crystallisation process in gels is aided by confined environments formed from the fibrous 
networks of gels [58]. These create microenvironments that facilitate solute-solute interactions 
and in some cases, the walls of these microenvironments (gel fibre network) can interact with 
solute molecules to act as nucleation “catalysts”, lowering the nucleation barrier of a 
polymorph. Furthermore, the results of this study suggest that polymorph selectivity can be 
obtained from nucleation arising from specific polymer-solute interactions which are 
facilitated by an optimum spatial configuration (Fig. 2.1.3). In this case the confinement effect 
created by the gel network provides the spatial configuration necessary to facilitate polymer-
solute interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.3. (a) and (b) are surface structures of form II facets preferentially nucleated on 
polymer surfaces. (c) Surface structure of a facet characteristic of form I not grown from 
polymer surface. (d) Functionality in CBZ inferred to interact preferentially with PEGDA 
polymer (coloured blue). Image and caption are a reprint from [58]. 
 
 
(a) 
(b) 
(c) (d) 
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2.1.3 Magnetorheological Fluids. The knowledge that confinement effects can facilitate 
polymer-solute interactions allows for the possibility of designing nucleation substrates. This 
led us to consider magnetorheological fluids as a means of controlling crystal polymorphism. 
Magnetorheological (MR) fluids are suspensions of magnetisable iron micro particles 
dispersed in a carrier fluid that exhibit the property of changing their rheology under a 
magnetic field [59]. Their relatively large size (up to 10 µm) means that they are magnetically 
multi-domain particles and hence do not possess a permanent magnetic dipole moment. 
Therefore, these suspensions exhibit a field-dependent change in rheology, displayed by an 
increase in viscosity and display of yield stress. Phulé and Ginder reported a yield stress of 
100 kPa at a 10,000 G field for 40 vol. % iron-based MR fluids [60]. In contrast, in the 
absence of a magnetic field, i.e. the “off” state, the MR fluids exhibit viscosities similar to that 
of the carrier fluids. 
The properties of these materials have attracted considerable attention in mechanical 
engineering as active devices that can be used to reduce mechanical vibrations. MR fluids are 
employed in active suspension, like that found in vehicles, and other dampers. The MR fluids 
act by performing real-time adjustments in the viscosity of a carrier fluid, in most cases oil, in 
order to affect the pressure exerted on a piston. The piston itself is an electromagnet with 
small channels that allow fluid to pass through (Fig. 2.1.4). This piston is immersed in an MR 
fluid, and as force from the vehicle is exerted on to the piston, a computer adjusts the magnetic 
field necessary to affect the rheology of the fluid and hence control the motion of the piston 
[61].  
 
 
 
 
 
 
 
 
Figure 2.1.4. Schematic Representation of a magnetorheological damper. Reprint from [62] 
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Unfortunately, a major drawback of MR fluids is their tendency towards sedimentation in 
the absence of a magnetic field. Their high density and large size means that keeping the 
particles evenly dispersed is a challenge and hence much of the research into these fluids has 
been towards affecting their density [63]. 
MR fluids affect viscosity by creating confined environments from the self-assembly of 
particles into chains along the direction of magnetic flux. The application of a magnetic field 
induces a magnetic dipole in each particle, causing them to assemble into chains, thereby 
preventing the flow of fluid (Fig. 2.1.5) [64]. These assemblies can be considered more 
ordered versions of a fibrous gel network, whereby the size of the confined environment is 
dependent on the magnetic field.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.5. Schematic Representation demonstrating the MR effect in response to a magnetic 
field. 
 
Furthermore, as a result of efforts to reduce the sedimentation of MR fluids, it has been 
shown that the surface of these iron micro particles can be modified with a variety of 
functionalities [65]. The ability to modify the surface of these particles opens up the 
possibility of designing interactions between particles and solute (drug) molecules. 
 
Direction of Magnetic Flux 
Carbonyl iron particles form chains 
in direction of magnetic flux 
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2.2 Adapting Magnetorheological Fluids for Crystallisations. Favourable active 
pharmaceutical ingredient (API) properties are defined by chemical purity and physical 
properties such as crystal habit and size, crystal structure and degree of crystal imperfection 
[43]. The physical characteristics of a crystal can be improved by creating a crystallisation 
media that promotes the suppression of convection currents, sedimentation and nucleation 
rates. A tuneable crystallisation medium would not only improve the physical characteristics 
of a crystal but also provide some control over polymorphism, enantiomorphism and other 
crystal habits [57]. Such a medium can be realised in low-molecular-weight supramolecular 
gels (LMWGs), whose inert matrix can support crystal growth. However, LMWGs have the 
disadvantage of incorporating into the crystal matrix and recovery of the crystals requires 
several washing steps that can damage or dissolve the crystals in the process. Alternatively, 
magnetorheological (MR) fluids can provide the confinement necessary to facilitate crystal 
growth, with the added advantage of an easy separation of crystal and iron particles, as the 
particles can be magnetically separated. 
The potential of MR fluids as a medium for crystal growth remains unexplored. Herein we 
propose the use of MR fluids as reversible “gelators” for the control of crystal growth in active 
pharmaceutical ingredients (APIs). We propose tuning the interactions between the MR fluid 
and the growing crystal by introducing a diverse array of functionalities onto the iron micro 
particle surface.  
 2.3 Properties of Carbonyl Iron (CI) Particles. The form of iron particles employed 
in this study is commonly referred to as carbonyl iron. Carbonyl iron (CI) is a highly pure iron 
prepared by the chemical decomposition of iron pentacarbonyl. The process is based on the 
fact that at a temperature of 300 ˚C iron pentacarbonyl vapours decompose according to the 
reaction in Fig. 2.3.1. This process produces a powder containing a range of particle sizes. The 
manufacturing process ends with a milling and size classification step that results in a narrow 
size distribution. CI is manufactured and distributed by BASF and Sigma Aldrich and can be 
obtained in sizes ranging from 1 to 6 µm. In this study we use CI obtained from Sigma 
Aldrich with a reported particle size of 1 – 3 µm and a bulk density of 7.86 g/cm3. SEM 
analysis revealed CI particles to be spherically uniform and of an average size distribution of 1 
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– 3 µm, with the odd appearance of particles smaller than 1 µm, likely due to the milling and 
separation process employed by Sigma Aldrich (Fig. 2.3.2). 
 
 
 
Figure 2.3.1. Reaction scheme for the decomposition of iron pentacarbonyl. 
 
 
 
Figure 2.3.2. SEM images of bare carbonyl iron particles. 
 
The magnetism of the particles was confirmed when during the preparation of an MR fluid a 
nearby neodymium magnet was attracted to the fluid and broke the container. The degree of 
magnetization in response to a magnetic field is known as magnetic susceptibility and is 
represented as a dimensionless proportionality constant. The extreme magnetic behaviour of 
our sample of CI made it clear that magnetic susceptibility measurements could prove 
difficult, since the measurement relies on the response of very sensitive magnets. Inserting a 
ferromagnetic substance like CI into a magnetic susceptibility scale could permanently 
damage it. It may be possible to dilute a sample in an inert gel media to collect a 
Fe(CO)5
NH3
300 ˚C Fe   +    5 CO
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measurement; however, this measurement may not be reliable as an absolute value for the 
material. The magnetic susceptibility of CI of this size has been reported in the literature as 
1.63 – 3.00 SI [66]. 
An MR fluid is made up of two main components, the carrier fluid and the magnetic 
iron particles, in this case CI. The behaviour of MR fluids in the absence of a magnetic field is 
similar to that of the carrier fluid, except that the presence of CI makes the fluid a bit more 
viscous. It is the fluid’s increase in viscosity and display of yield stress under a magnetic field 
which is characterised as the magnetorheological effect. In this work, MR fluids were 
prepared from CI iron (bare or modified) particles in 40 wt. % concentrations in a toluene or 
water carrier fluid. Initial experiments utilised silicone oil as the carrier fluid, however, for 
crystallising drug molecules this was changed to toluene. The samples were prepared in small 
vials, shaken to disperse the particles evenly, and then placed in between the poles of an 
electromagnet from a Bruker EMX EPR instrument (Fig. 2.3.3). 
 
 
Figure 2.3.3. Schematic Representation of MRF setup 
 
This instrument provides a homogeneous field throughout the sample area, unlike a 
small permanent magnet where the magnetic field varies with distance from the source. In 
toluene, a 100 G field produced increases in viscosity which were significant enough to 
demonstrate a decrease in fluid flow, but not significant enough to immobilise the fluid, which 
we observed by simply inverting the container. To obtain fluid immobility in toluene a 
magnetic field strength of 200 G is required. The absence of a magnetic field results in the 
Direction of Magnetic Field 
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sedimentation of the particles in a matter of seconds (Fig. 2.3.4a and d) and a 1000 G field 
results in a very strong magnetorheological effect that maintains the CI particles evenly 
dispersed in the carrier fluid (Fig. 2.3.4b). Inversion of the container at 1000 G shows the 
immobility of the carrier fluid, but also reveals a layered structure (Fig. 2.3.4c). This layered 
structure was only revealed at 1000 G because the container was inverted while in the field, 
however, we observed behaviours like the one in Fig. 2.3.4c at field strengths above 1000 G, 
where the layers became more defined at higher field strengths. We observed that as the field 
strength was increased, the layers became visible and more uniform in size, while at lower 
field strengths the layers were of random sizes. Unfortunately, we did not measure the gap 
sizes, nor did we investigate the phenomenon further. 
Although not visible at or below 1000 G, these layers represent the mechanism by 
which fluid immobility is attained. The self-assembly of CI particles into chains induced by a 
magnetic field (Fig. 2.1.5) create pockets which trap the carrier fluid. Removing the container 
from the magnetic field demonstrates that the CI particles sediment in the absence of a field, 
and the carrier fluid returns to its original viscosity (Fig. 2.3.4d). 
 
 
 
 
 
 
 
 
Figure 2.3.4. Images displaying MR fluid in (a) 0 G field, (b) 1000 G field, (c) upside-down in 
1000 G field and (d) upside-down in 0 G field. 
 
 
2.4 Surface Modification of Carbonyl Iron. Sedimentation of CI in an MR fluid is 
mainly due to the large density and size of the micro particles. A lower sedimentation rate 
would facilitate the handling of these fluids in the absence of a field. To improve the particles’ 
colloidal stability a high molecular weight polymer can be adsorbed to the particle surface to 
(a) (b) (c) (d) 
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decrease the particle’s overall density and increase interactions with the solvent molecules. 
We chose a PEG functionality because of its relatively simple synthesis and high-water 
solubility. Owing to the reports of facile surface modification of iron oxide nanoparticles with 
nitrodopamine anchors, we decided to attach nitrodopamine to our PEG functionality, because 
our CI particles most likely have oxidised surfaces. 
First, acid terminated poly(ethylene glycol) methyl ether 5000 (mPEG) was prepared 
by modification of the hydroxyl end group of mPEG with succinic anhydride to generate the 
carboxyl end group (Fig. 2.4.1). Subsequently, the nitrodopamine molecule was coupled to the 
carboxylated mPEG through a conventional uronium reaction with COMU to generate mPEG-
NDA (Fig. 2.4.1) [67,68]. The characteristic peaks of mPEG, carboxylated mPEG and mPEG-
NDA were observed by FTIR and NMR at each step of the synthesis (Fig. 2.4.2). 
 
 
 
 
 
 
Figure 2.4.1. Synthetic scheme for Nitrodopamine PEG 
 
In Fig. 2.4.2, the bands attributed to the C-O bond in ether are highlighted by a green box; the 
blue box indicates the presence of C=O of carboxylic acid and the orange box shows both the 
C=O bond in carboxylic acid (1734 cm-1) and the C=O bond of the amide (1645 cm-1) from 
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the addition of nitrodopamine. The presence of both bands at 1645 and 1734 cm-1 in mPEG-
NDA indicated that not all the carboxylated mPEG was coupled to nitrodopamine. UV-Visible 
spectroscopy analysis was performed by creating a dilution series of nitrodopamine in PBS. 
Concentrations ranging from 18.75 µM to 150 µM were prepared and the peak absorbances at 
425 nm were used to plot a calibration curve. We then prepared a 300 µM sample of mPEG-
NDA in PBS and measured the absorbance at 425 nm. Using the formula obtained from the 
calibration we determined that only 20% of the carboxylated mPEG had been successfully 
converted to mPEG-NDA (Fig. 2.4.3).  
 
 
 
 
 
Figure 2.4.2. FTIR spectra mPEG, Carboxylated mPEG and mPEG-NDA 
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Figure 2.4.3. (a) UV-Visible absorption spectra of functionalised mPEG-NDA and (b) 
calibration curve obtained from UV-Visible spectra of nitrodopamine (NDA). 
 
This result may explain the absence of nitrodopamine peaks in 1H NMR Spectra. To remedy 
this low conversion, the experiment was repeated with an excess of coupling agent, COMU. 
Modification of the synthesis resulted in a 53% conversion of carboxylated mPEG to mPEG-
NDA. The chemical structures and compositions of the synthesised polymers were determined 
by 1H NMR spectroscopy (Fig. 2.4.4). The resonances at 3.36 and 3.62 ppm were attributed to 
CH3-O and -O-CH2-CH2-O protons respectively in the mPEG unit. 
 The resonances of the -CH2-CH2- protons from the addition of succinic anhydride 
appeared at 2.62 ppm (Fig. 2.4.4b), and the appearance of two singlet peaks at 6.77 and 7.66 
ppm (Fig. 2.4.4c) associated with the two protons in the aromatic ring of the nitrodopamine 
molecule confirm the conversion to mPEG-NDA. 
 
 Additional confirmation of the formation of carboxylated mPEG and mPEG-NDA was 
provided by performing mass spectrometry at each step of the synthesis (Fig. 2.4.5). As can be 
seen from the zoomed-in regions in Fig. 2.4.5, mass peaks of a series are separated by the 
monomer weight of PEG, 44 Da. 
 
 
425 nm 
(a) (b) 
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Figure 2.4.4. 1H NMR Spectra of (a) mPEG, (b) carboxylated mPEG and (c) mPEG-NDA in 
CDCl3. 
It is possible to take a peak from the MALDI fingerprint for mPEG, add the mass 
corresponding to the addition of succinic anhydride (100 Da), and subtract the monomer 
weight of PEG (44 Da) until you arrive at a peak observed in the fingerprint for carboxylated 
mPEG. For example, if we take the peak at 5430 in the spectrum for mPEG and add 100 
(corresponding to the addition of succinic anhydride) we get 5530, which is a peak observed 
in the spectrum for carboxylated mPEG (Fig. 2.4.5). Subtracting 44 (monomer weight of PEG) 
we get 5486, which is also observed in the fingerprint of carboxylated mPEG. This confirms 
that the fingerprint obtained is a result of the addition of succinic anhydride. The same can be 
done with mPEG-NDA, except that we add the mass corresponding to the addition of 
nitrodopamine (166 Da). Using this method, we were able to confirm the conversion of mPEG 
to carboxylated mPEG and mPEG-NDA. The peaks in each fingerprint line up with the peak 
positions expected for each step of the synthesis. 
(c) 
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Figure 2.4.5. MALDI-TOF mass spectra of mPEG, carboxylated mPEG and mPEG-NDA. 
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However, the broad line-shape and lack of resolution observed at each conversion step 
indicates that some starting material remains at the end of the reaction.  
2.5 Surface Modification of Carbonyl Iron with mPEG-NDA. To graft polymer 
chains onto CI particles, mPEG-NDA (20 mg) was sonicated with bare CI particles (1 g) in 20 
mL of pH 7 phosphate buffer solution (PBS) for 8 h. Grafting densities for mPEG-NDA on 
iron oxide nanoparticles have been reported at (0.5 –2) × 10* chains/µm2 [68]. Using the 
higher estimate of 2 × 10* chains/µm2, we calculated the mass of chains on a CI particle with 
a diameter of 2 µm and then calculated the ratio of particle mass to mass of chains 
[Appendix]. By this method, it was calculated that the mass of polymer required was 
approximately 0.70% of the mass of CI used. A 7 mg excess of polymer (i.e. 14 mg) was used 
to facilitate functionalisation. 
To determine if functionalisation was successful, 1 mL aliquots of the reacting solution 
were taken every hour and examined using UV-Visible absorption spectroscopy. Fig. 2.5.1a 
shows the results of this experiment at 0, 2 and 3 h. It is clear from the graph that the 
absorption band of nitrodopamine at 425 nm is replaced by a continuum that precludes 
positive assignment. The solution was centrifuged to remove the iron particles prior to 
analysing the mother liquor, therefore the absorption continuum is likely due to a leachate. It 
was also clear that the signal for nitrodopamine disappeared before the 2 h mark and that the 
pH of the solution had increased from 7 to 9.  
To improve functionalisation, nitrodopamine anchors were complexed with carbonyl 
iron in dimethylformamide (DMF) because iron particles have greater colloidal stability in this 
solvent compared to PBS – due mainly to the fact that PBS causes aggregation of iron 
particles due to the strong interaction of phosphates with iron ions. Also, the greater viscosity 
of DMF results in improved colloidal stability [69, 70]. It should be noted that the absorption 
band corresponding to nitrodopamine shifts from 425 nm in PBS to 445 nm in DMF. 
 The grafting of polymer chains onto CI particles was attempted in DMF by sonicating 
mPEG-NDA (20 mg) with bare CI particles (1 g) in 20 mL of DMF. Functionalising a sample 
of bare-CI with mPEG-NDA in DMF showed a decrease in the intensity of the absorption 
band at 445 nm (Fig. 2.5.1b), indicating a depletion of nitrodopamine after 20 min, which 
suggests that functionalisation was beginning to take place on bare-CI particles. However, the 
previously observed absorption continuum increased after 40 and 60 min, indicating that 
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leaching from the particle surface was still taking place. This eventually led to the obstruction 
of the signal at 445 nm. Using Beer’s law, we calculated the mass of mPEG-NDA grafted onto 
CI in the first 20 min [Appendix]. The decrease in absorbance at 445 nm from 0 to 20 min was 
consistent with a 0.51 mg depletion of mPEG-NDA (Fig. 2.5.1b). This result would indicate a 
7.3% functionalisation efficiency; however, this cannot be taken as the absolute efficiency as 
particle leachate obstructed further analysis of the peak at 445 nm. The resultant particles from 
the functionalisation in DMF were filtered and dried and made into an MR fluid. MR fluids 
were prepared by mechanically stirring 1 g of CI with 1.56 mL of silicone oil. A mPEG-NDA 
MR fluid was prepared and compared against a bare CI control, however, both exhibited 
similar sedimentation rates, which we observed by visually monitoring the samples over a 1 h 
period. Thermogravimetric analysis of this sample also failed to confirm the presence of 
polymer as the expected 0.70% change in weight was virtually undetectable by this method. 
We observed no marked decrease in the sedimentation rate when comparing the 
mPEG-NDA MR fluid with our bare CI control, which suggested that the particles were too 
large to be affected by the polymers. Nevertheless, the labour-intensive nature of 
functionalisation with nitrodopamine anchors led us to explore other methods for surface 
modification of CI. 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.5.1. UV-Visible absorption spectra during functionalisation with mPEG-NDA of (a) 
bare CI in PBS, (b) bare CI in DMF. 
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Successful functionalisation of carbonyl iron (CI) particles with oleic acid has been 
demonstrated before [71,72]. Modifying CI particles with oleic acid was done by sonication of 
CI (1 g) and oleic acid (large excess, 3 mL) in 20 mL ethanol at 40 ˚C for 3 h. The 
hydrophobic behaviour of the resultant powder (Fig. 2.5.2) suggested that carboxylic acid 
moieties could provide a more facile means of modifying CI surfaces. Furthermore, changes in 
hydrophobicity could serve as an indicator of functionalisation. We probed the hydrophobicity 
of CI samples by taking a 200 mg sample, compressing it with a glass microscope slide, and 
then placing a 1 mL drop of water on the surface. Although only qualitative, this measurement 
provides evidence of changes to the surface properties of functionalised CI when compared to 
bare-CI. Considering the powder-like nature of CI it was not possible to reproducibly obtain 
contact angle measurements, and hence we were forced to rely on this qualitative analysis of 
hydrophobicity as an indicator of functionalisation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.2. (a) optical image of water droplet on powder of oleic acid functionalised CI and 
(b) a graphical representation of functionality attached to the particle surface. 
 
2.6 Surface Modification with Carboxylic Acid Moieties. The fundamental 
procedure for the functionalisation of CI with carboxylic acid moieties was adapted from the 
technique used by Huang et al. [71]. In our adapted procedure, CI (5 g) and the carboxylic 
acid-terminated moiety (1 g) were sonicated in ethanol at 40 ˚C for 3 h under a nitrogen 
atmosphere. The solution was then centrifuged and washed several times with the appropriate 
(a
) 
(b
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solvent, before being filtered and dried. CI was functionalised by this method with the acid 
terminated PEG (carboxylated mPEG) synthesised previously, carminic acid, 1-
napthaleneacetic acid and oleic acid (Fig. 2.6.1). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6.1. Carbonyl iron functionalities employed in this study. (a) Carboxylated mPEG, 
(b) carminic acid, (c) 1-napthaleneacetic acid and (d) oleic acid. 
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To determine the amount of ligand adsorbed on to the CI surface, hydrolysis of the ligand in 
carboxylated mPEG functionalised CI (mPEG-CI) was performed in a 2 M solution of sodium 
hydroxide. This was done by stirring a 4 g sample in a 50 mL alcoholic solution of sodium 
hydroxide (2.0 M, methanol/water 9/1) for 24 h at RT. By hydrolysing the ester bond in the 
PEG ligand, we were able to release free PEG from the particle surface into solution that could 
be simply quantified using 1H NMR spectroscopy as shown in Fig. 2.6.2. The results of this 
analysis are detailed in Table 2.6.1, where 4 g of PEG-CI was hydrolysed to release 0.54 ± 
0.06 mg of PEG. From this result it was calculated that the grafting density for carboxylated 
mPEG onto CI micro particles was 3.9 ×	104 chains/µm2. 
 
 
 
 
 
 
 
 
 
Figure 2.6.2. Schematic Representation for the quantification of PEG adsorbed onto CI 
 
Table 2.6.1. Quantitative NMR Spectroscopy results from the hydrolysis of PEG-CI 
 (a)For the calculation of grafting density it was assumed that the average particle size was 2 µm and that the 
molecular weight of carboxylated mPEG was 5486 g/mol from (Fig. 2.4.5). 
Particle Sizes (µm) Functionality Mass Calc. by 
qNMR (mg) 
Grafting Density(a) 
(Chains/µm2) 
1-3 Carboxylated mPEG 0.54 ± 0.06 3.9	×	104 
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Carminic acid and 1-napthaleneacetic acid were chosen because of their drastically 
different polarities and the presence of a carboxylic acid terminus, which make them capable 
of forming coordination bonds with CI [73]. The behaviour of functionalised CI to a drop of 
water can be seen in Fig. 2.6.3. Carminic acid functionalised CI (carminic acid-CI) and acid-
terminated-mPEG CI (PEG-CI) powders exhibited more hydrophilic behaviours compared to 
1-napthaleneacetic acid-CI (naphthalene-CI) (Fig. 2.6.3) and oleic acid-CI (Fig. 2.5.2).  
SEM analysis showed the surfaces of coated particles (Fig. 2.6.4) to be rougher than 
bare particles (Fig. 2.3.2), due mainly to etching of the particle surface by the acidic 
environment. The carminic acid-CI and naphthalene-CI seemed to retain more of the original 
shape of CI compared to the PEG-CI (Fig. 2.6.4c), which produced more irregularly shaped 
particles. 
  We were able to demonstrate the depletion of carminic acid in the presence of 100 mg 
of CI by monitoring the absorbance of a 5 ppm solution of carminic acid over a period of 12 
min (Fig. 2.6.5). We observed a decrease in the intensity of the absorption band for carminic 
acid at 278 nm every 4 min which indicated carminic acid groups were adhering to the CI 
particles. The shifting of the peak to higher wavelengths over time is attributed to a substance 
leaching from the particles that affected the pH of the solution, and hence we could not 
provide an accurate quantitative analysis.  
In a report by Zirbs et al., it was shown that the maximum grafting density attainable 
with PEG (5 kDa) on iron oxide nanoparticles is approximately 3 ×	106 chains/µm2. 
Furthermore, grafting densities > 5 ×	105 chains/µm2 for PEG-dispersants in the 3-10 kDa 
range have been reported as necessary for colloidal stability [37]. Therefore, the grafting 
density we obtained in our CI particles was too low to significantly affect the colloidal 
stability of the micro particles, however, it may be dense enough to interact with an active 
pharmaceutical ingredient (API) during crystallisation. 
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Figure 2.6.3. Optical image of water droplet on powder of (a) mPEG-CI, (b) 1-
naphthaleneacetic acid-CI and (c) carminic acid-CI. 
 
 
(a) 
(b) 
(c) 
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Figure 2.6.4. SEM images of (a) Carminic acid-CI, (b) 1-naphthaleneacetic acid-CI and (c) 
PEG-CI. 
(a) 
(b) 
(c) 
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Figure 2.6.5. UV-Visible absorption spectra during the functionalisation of CI with carminic 
acid. 
2.7 Crystallisation of Carbamazepine in Toluene MR Fluids. In this study we 
examined the anticonvulsant drug carbamazepine (CBZ) because it is an active pharmaceutical 
ingredient (API) which serves as a model compound for many studies on polymorphism [74, 
75]. CBZ’s bioavailability has been shown to be dependent on the polymorph administered, 
and therefore its polymorphism plays a crucial role in pharmacokinetics [76]. There are four 
known polymorphs of CBZ, the details of which are summarised in Table 2.7.1, each of which 
demonstrate different thermal stabilities. It has been shown that the most stable of the 
polymorphs at room temperature is the monoclinic form III, the commercially available form, 
and the only one which exhibits the desirable therapeutic effects [77].  
We wanted to determine if MR fluids can be used to affect the polymorphism of CBZ 
during crystallisation. To do this, we needed to determine if the particle functionality 
interacted with the API to affect the packing of the crystal units and promote one crystal habit 
over another. 
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Table 2.7.1. Known polymorphs of Carbamazepine (CBZ)(b). 
(b)Data was collected from [78] and formatted according to [57]. 
Crystallisation of CBZ was initially performed in 1.73 mL of toluene containing 1 g of 
CI and 20 mg of CBZ. This solution was sonicated for 1 min and placed into a 70°C water 
bath for 10 min, after which the CBZ had dissolved. The solution was then shaken to disperse 
the particles and immediately placed in-between the poles of an EPR magnet (like in Fig. 
2.3.3) using a Styrofoam support, for 12 h, in a 21 ˚C air-conditioned room. Control 
crystallisations of CBZ under identical conditions, i.e. without CI, were performed in parallel. 
Crystallisations were performed at 200 and 1000 G, where the higher magnetic field resulted 
in higher MR fluid viscosities. We observed that under control conditions (no CI), the crystal 
habit was evenly populated by needles and blocks (Fig. 2.7.1), which we later confirmed by 
XRD to be the monoclinic form III (block) and trigonal form II (needle). 
 
 
 
 
 
 
 
Figure 2.7.1. Optical microscopy (10x magnification, 1.6 mm field of view) of CBZ grown in 
toluene containing no CI. 
Form Space Group Habit Stability Order Crystallisation Method 
I Triclinic P1 Needle 2 Melt at 192 ˚C 
II Trigonal R3 Needle 4 Cooled (5 ˚ C) from ethanol 
for 5 h 
III Monoclinic P21/c Block 1 Slow evaporation from 
ethanol 
IV Monoclinic C2/c Prism 3 Slow evaporation from 
ethanol in the presence of 
hydroxypropyl cellulose 
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The magnetorheological (gelation) effects on crystal habit became apparent when 
crystallisation in a bare-CI MR fluid resulted in a shift in crystal habit from block and needle 
to predominantly needle (Fig. 2.7.2a). An effect of particle functionalities on crystal 
morphology was observed when crystallisation in oleic acid grafted particles (oleic acid-CI) 
shifted the crystal habit completely towards block, both at 200 (Fig. 2.7.2c) and 1000 G (Fig. 
2.7.3c), and the crystallisation in PEG-CI (Fig. 2.7.2b and 2.7.3b) and bare-CI (Fig. 2.7.2a and 
2.7.3a) produced needle structures. Control experiments containing toluene and 20 µL of oleic 
acid showed needle formation as opposed to blocks, confirming that the combined effect of 
gelation and particle functionalities is responsible for the crystal habit shift (Fig. 2.7.3d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7.2. Optical microscopy (10x magnification, 1.6 mm field of view) of CBZ grown in 
toluene containing (a) bare CI, (b) PEG-CI and (c) Oleic acid-CI in a 200 G magnetic field. 
 
(a) 
(b) 
(c) 
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Figure 2.7.3. Optical microscopy (10x magnification, 1.6 mm field of view) of CBZ grown in 
toluene containing (a) bare CI, (b) PEG-CI, (c) Oleic acid-CI and (d) 20uL of Oleic acid in a 
1000 G magnetic field. 
 
 
(a) 
(b) 
(c) 
(d) 
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Comparisons of the optical images in Fig. 2.7.2 (200 gauss) and Fig. 2.7.3 (1000 
gauss) reveal few differences between these crystals. However, it can be noted that the 
crystallisations at 200 G produced slightly larger needles than those at 1000 G, and that the 
block formations at 1000 G had more flat surfaces (Fig. 2.7.3c).  From this result we can see 
that the magnetic field strength has little effect on crystal habit and the cause of the effect of 
particle functionalities on crystal habits is not clear.  
To better understand the effect of particle functionality on CBZ crystal habits we 
considered the molecular packing of each form (Fig. 2.7.4). It is important to note that the 
differences among crystal forms lies solely in the packing of the carboxamide dimer units, 
described by the pattern of weak hydrogen bonding interactions present in all the forms [78]. 
The polymorphism between the triclinic and trigonal (needle) morphologies arises from the 
alternative packing of these dimers, where they are packed with offset π-π stacking of the 
aromatic rings (Fig. 2.7.4a and 2.7.4b). In the monoclinic forms the dimer units pack edge-to-
face π-π stacking of the aromatic rings (Fig. 2.7.4c and d).  
We therefore extended this concept to study the effect of a non-polar aromatic 
functionality, 1-naphthaleneacetic acid, and a polar aromatic functionality, carminic acid. 
Crystallisations of CBZ were performed in naphthalene-CI and carminic-CI at 1000 G under 
conditions identical to previous crystallisations. 
The results of these crystallisations (Fig. 2.7.5) suggest that a functionality with no 
potential for hydrogen bond donation, in this case the non-polar naphthalene, results in a shift 
towards a block crystal habit (Fig. 2.7.5b). At the same time, a functionality with hydrogen 
bond donating potential, the polar carminic ligand, results in a needle crystal habit (Fig. 
2.7.5a). This indicates that hydrogen bonding interactions between the API and the particle 
functionality are more significant than π-π interactions in affecting crystal habit. Furthermore, 
it can be readily seen from the results summarised in Table 2.7.2 that functionalities with no 
hydrogen bond donating potential like oleic acid and 1-napthaleneacetic acid, produce a shift 
towards block crystal habits, while functionalities with the ability for hydrogen bond donation 
result in needle formations. The lack of hydrogen bond donators in the oleic and naphthalene 
functionalities means that π-π interactions between the CBZ dimer units dominate and 
determine crystal habits. 
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Figure 2.7.4. Packing diagrams of (a) form I, (b) form II, (c) form III and (d) form IV of CBZ 
showing hydrogen-bonding patterns. Reprint from [78]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7.5. Optical microscopy (10x magnification, 1.6 mm field of view) of CBZ grown in 
toluene containing (a) carminic-CI, (b) naphthalene-CI in a 1000 gauss magnetic field. 
(a) 
(b) 
(a) (b) 
(c) (d) 
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Table 2.7.2. Summary of crystallisations of CBZ in toluene MR fluids at 1000 gauss. 
(c)Space groups were determined by running a pre-experiment data collection on a Rigaku Oxford XRD 
instrument. 
Favourable interactions between particle functionality and solute molecules (API) may direct 
the CBZ molecules toward an orientation that reduces the entropic cost of nucleation and 
therefore the particles may serve as active nucleation sites [58]. 
There is work on the polymorphism of calcium carbonate in chitosan gels that 
indicates that the gel may act as a high energy surface capable of actively nucleating new 
crystal forms. The nucleation of the vaterite form at the interface of the chitosan gel is 
stabilised through hydrogen bonding interactions with other flexible chitosan chains [79]. It is 
possible that the CI particles act as nucleation sites onto which successive layers of CBZ can 
deposit and become stabilised through hydrogen bonding interactions with the CI 
functionalities. Extending this concept may help to explain the variations observed in crystal 
clarity. For example, some of the crystals, particularly the block formations, appeared dark in 
colour and seemed to be speckled with CI particles (Fig. 2.7.2c, 2.7.3c, 2.7.5b). In fact, 
crystals grown in oleic acid and naphthalene functionalities seem to contain more CI particles 
than those grown in PEG-CI or carminic-CI. The observation that crystals grown in the 
presence of non-polar functionalities retain more carbonyl iron particles is evidence of an 
attractive force between the particle functionality and CBZ. Taking into account the fact that a 
lack of hydrogen bond donators in these functionalities means that π-π interactions dominate; 
it is likely that these π-π interactions cause CBZ to crystallise by nucleating on the CI 
particles, rather than on defects native to the container. 
2.8 Crystallisation of Carbamazepine in water MR Fluids. In distilled water the 
solubility of CBZ is significantly lower than in Toluene. Optimising conditions for 
Functionality Habit Space Group(c) Form 
Pure Toluene Mixed Needle and Block Trigonal R3 II + III 
Bare Needle Trigonal R3 II 
Carboxylated mPEG Needle Trigonal R3 II 
Carminic Acid Needle Trigonal R3 II 
Oleic Acid Block Monoclinic P21/c III 
1-Napthaleneacetic Acid Block Monoclinic P21/c III 
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crystallisation in water required a decrease in the amount of CBZ to 5 mg, however all other 
procedures for crystallisation of CBZ remained the same. Under these conditions we observed 
that crystal habit was only influenced by the effect of gelation, which was responsible for the 
shift in crystal habit from needle (Fig. 2.8.1a) to block (Fig. 2.8.1b-f). The particle 
functionalities were rendered ineffective, as the block crystal habit was observed in the bare 
and functionalised CI. It is likely that the use of a polar solvent, i.e. water, out-competed the 
hydrogen bonding effects of the functionalities leading to one crystal habit. We posit that the 
hydrogen bonding interactions of CBZ with water directed the orientation of CBZ molecules 
causing them to nucleate in a way that produced block formations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
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Figure 2.8.1. Optical microscopy (10x magnification, 1.6 mm field of view) of CBZ grown in 
water containing (a) pure solvent, (b) Bare-CI, (c) PEG-CI, (d) Oleic acid-CI, (e) Carminic-CI 
and (f) Naphthalene-CI in a 1000 G magnetic field. 
 
Furthermore, the confinement effect of gelation coupled with the hydrogen bonding 
interactions with water likely created an environment which entropically preferred a block 
habit. 
2.9 Separation of CBZ Crystals from MR Fluid. Magnetorheological fluids have the 
advantage of being reversible. These fluids can be switched “on” or “off” by a magnetic field, 
and it is this reversible nature that allows for easy recovery of crystals. In our experiments, the 
crystals were collected by magnetically separating the particles from the carrier fluid and 
filtering. The particles were rinsed several times with the carrier fluid, sedimented using a 
neodymium magnet, and the solution was filtered to collect the crystals. In contrast, LMWG 
and hydrogels require the use of solvents, or in some cases gel removal may involve acid 
hydrolysis or heating [80]. These methods of separation can permanently damage the crystals 
and therefore have serious limitations. Our method is only limited by the possible interactions 
between carrier fluid and CI particles, for example low pH fluids may dissolve the CI. Overall, 
MR fluids can serve as effective crystallisation media for API. 
(e) 
(f) 
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2.10 Conclusion. We have demonstrated the use of magnetorheological fluids as a 
medium for crystal growth. The reversible nature of the MR effect allows for the facile 
recovery of crystals. The observation that carboxylic acid moieties can be used to modify the 
surfaces of CI particles provides the ability to design an MR fluid to match a wide range of 
crystallisation conditions. Clear differences in crystal habit were observed as a result of 
varying CI particle functionalities, indicating that control of polymorphism is possible. 
However, the exact nature of the interactions between functionality and API have not yet been 
determined. Nevertheless, by introducing different particle functionalities, we were able to 
control the crystal habits of CBZ in toluene MR fluids. 
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Chapter 3. Synthesis and Surface Modification of Magnetite (Fe3O4) Nanoparticle 
clusters 
3.1 Background. MRI-guided magnetic thermotherapy exploits the heat generation 
ability and magnetic properties of biocompatible iron oxide (Fe3O4) to facilitate local cellular-
level heating of deep tumours. The actual therapeutic effects of magnetic hyperthermia 
treatments depend on the heating efficiency of magnetic nanoparticles (MNPs). These MNPs 
can generate heat via hysteresis loss, Neél relaxation and Brownian relaxation under the 
influence of an alternating magnetic field (AMF). The levels of heat-generation required to 
raise tumour temperatures to values lethal to cancer cells (above 42.5 ̊C) cannot be realized by 
the most conventional biocompatible iron oxide nanoparticles [81, 82]. It is known that heat-
generation power of nanoparticle clusters is related to the strength of magnetic-dipole 
interactions between nanoparticles in the cluster and that the magnetic dipole interaction 
energy is inversely proportional to particle-particle separation (𝑙): 
𝐸 = −(𝜇!𝑚!+)(4𝜋𝑙,)  
where 𝜇! is the magnetic permeability of a vacuum and 𝑚! is the magnetic moment [83]. 
Therefore, decreasing particle-particle separation can enhance heat-generation power. This 
theory led Hayashi et al. to create a “tight” clustering of magnetic NPs with zero particle-
particle separation – significantly increasing the heat-generation efficiency of magnetite 
(Fe3O4). 
 An alternative application of magnetic heating for cancer cell death is to use the local 
heating afforded by nanoparticles to trigger a phase transition in a polymer coating, and hence 
release an anticancer drug [84].  Crucially, for biocompatibility, a highly solvated polymer 
brush must be used to suspend the nanoparticles in biological media. Poly-N-isopropyl 
acrylamide (PNIPAM) provides a good alternative to the more commonly used PEG 
functionality as it provides the high aqueous solubility necessary to disperse nanoparticles, but 
also exhibits a drastic change in solvation at ~32˚C, referred to as its low critical solution 
temperature. Low critical solution temperatures (LCST) describe the behaviour of polymer 
solutions which display a decrease in solubility with a rise in temperature. This phenomenon is 
(1) 
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due to an unfavourable entropy effect, where the entropy of mixing is negative, an input of 
heat energy results in a phase transition in the polymer resulting in a phase separation [85]. 
This low critical solution temperature (LCST) provides the means for a reversible 
temperature-induced aggregation of nanoparticles [68]. 
 The LCST behaviour of PNIPAM, coupled with the high heat generation efficiency of 
clustered magnetite particles can provide an efficient means to direct and concentrate 
nanoparticles in a tumour. In this chapter, we present the methods of synthesis and surface 
modification of iron oxide clusters. 
 3.2. Synthesis of Iron Oxide Clusters. We first attempted to recreate the literature 
procedure for the synthesis of iron oxide NP clusters [81]. The novelty in our study is based 
around the functionalisation of these clusters with a temperature sensitive polymer, which we 
cover later in this chapter (section 3.4). 
Iron oxide clusters were synthesised by first polymerising pyrrole-3-carboxylic acid 
(PyCOOH) using iron (III) ions as an oxidant in an aqueous solution of polyvinyl alcohol 
(PVA). According to Hong et al. PVA forms coordination bonds with iron cations in solution 
that form clusters of the water-soluble polymer and iron cations [86], this allowed the reaction 
to proceed according to dispersion polymerisation. The addition of pyrrole-3-carboxylic acid 
resulted in the formation of polypyrrole nanoparticles (PPy NPs) containing embedded iron 
(III) ions. Some of the iron (III) ions in the PPy NPs were then reduced and hydrolysed using 
hydrazine to produce Fe3O4 NPs encapsulated in a pyrrole polymer shell (Fig. 3.2.1) [86]. The 
particles were collected by centrifugation and redispersed in distilled water repeated three 
times to wash the NP clusters. The clusters were then stored in distilled water in centrifuge 
tubes at 4 ˚C in the dark. 
Dynamic light scattering (DLS) analysis was performed on the iron oxide clusters by 
sonicating the stock solution for 5 min and then taking 1 mL and diluting it into 4 mL of 
distilled water. The samples were left to equilibrate to room temperature and then sonicated 
for 5 min before collecting the data. DLS indicated that the clusters had an average 
hydrodynamic diameter of 133.1 ± 0.2 nm. NP clusters were observed by TEM by drying a 
droplet of the NP solution on a Cu TEM grid. TEM analysis revealed that cluster sizes were 
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significantly smaller than those observed by DLS. It can be seen from Fig. 3.2.2a that the 
clusters are significantly smaller than 133 nm and that they are surrounded by strings of 
nanoparticles linked together in a network. 
 
 
Figure 3.2.1. Schematic Representation of nanoparticle cluster synthesis 
 
Considering that the DLS instrument performs a measurement by assuming spherical 
particles, it isn’t surprising that our measurements registered this network as a single structure 
and hence recorded such large diameters. 
It is also clear from these images that clusters have begun to form, as shown by the 
concentration of dark structures (Fig. 3.2.2a). However, these iron oxide cores display non-
uniform size distributions with sizes ranging between 20-30 nm and lack any uniform shape. 
Furthermore, the strings of iron oxide NPs (Fig. 3.2.2a) observed in this sample were also 
incongruent with expected results, where monodisperse clustered structures were expected. 
The lack of uniform shape and size suggests that there is an issue with the step involving the 
formation of PPy NPs. Since the PPy NPs act as a scaffold for the iron oxide cores, the 
resulting shape and size of the PPy NPs should influence the morphology of the resultant 
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clusters. According to a study on the formation of PPy NPs [86], the complexation of iron 
cations to polyvinyl alcohol (PVA) is influenced by the PVA concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2. TEM images of (a) Fe3O4clusters prepared with 3.8% PVA, (b) Fe3O4 clusters 
prepared with 7% PVA and (c) Fe3O4 clusters functionalised with PNIPAM.  
 
(a) (b) (c) 
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It is considered that the complex becomes more sterically stable with increasing PVA 
concentration, where the chain conformation of the polymer switches from a random coil to 
globular (Fig. 3.2.3). Fig. 3.2.3 shows how the polymer adopts a more spherical tight-knit 
shape at higher PVA polymer concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.3. Changes in shape factor as a function of PVA concentration. Reprint from [86]. 
 
Following this reasoning the cluster synthesis was modified by increasing the PVA 
concentration from 3.8% to 7% in 10 mL of water, unfortunately, we were not able to 
reproduce this graph as increased PVA concentrations did not produce easily observable 
differences as seen in Fig. 3.2.2b. It can be readily seen from the separation of the dark black 
structures that more monodisperse clusters have formed (white circles). Although strings of 
nanoparticles are still present, they seem to be aggregating more than those in Fig. 3.2.2a. 
DLS analysis parameters were modified to account for the higher viscosity of PVA compared 
to water which put the cluster sizes at 91.14 ± 2.5 nm. However, TEM images indicate the 
clusters are no larger than 50 nm making it clear that the network of particle strings is still 
interfering with the DLS measurement. Nevertheless, functionalisation of the nanoparticles 
with a temperature sensitive polymer was attempted. 
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3.3 Polymer Synthesis and Characterization. To modify the nanoparticle cluster 
surfaces with poly-N-isopropyl acrylamide (PNIPAM), we had to modify the polymer with a 
termination that could be easily added to the carboxylic acid terminated surfaces decorating 
the clusters. Considering that COMU offers a facile and efficient method for amidation [87], 
we decided to add an amine termination to PNIPAM (Fig. 3.3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1. Coupling mechanism for COMU in the reaction between ethylenediamine and 
PNIPAM with DIPEA as the base. 
The acid terminated poly(N-propylacrylamide) (PNIPAM) was synthesised by atomic-
transfer radical-polymerization (ATRP) of NIPAM to obtain a 93% yield. The polymer was 
then modified with ethylenediamine using COMU as a coupling agent, resulting in an amine 
functionalised PNIPAM (A-PNIPAM) (Fig. 3.3.2). Excess amine was removed by dialysis to 
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facilitate characterization and the polymer was dried, resulting in a 23% yield. The low yield 
in the coupling of ethylenediamine to PNIPAM could not be explained. Repeat syntheses 
resulted in similar yields. 
 
 
 
 
 
 
 
 
 
 
 
The synthesis of acid terminated PNIPAM was confirmed by 1H NMR spectroscopy 
(Fig. 3.3.3a) where the resonances at 1.12, 2.46 and 3.99 ppm were attributed to CH3-C-CH3, 
-[CH2]n- and CH-Br, respectively. In Fig. 3.3.3, the colours in the spectra represent the 
agreement of the peaks with predicted values. Green indicates good agreement and yellow 
indicates weak agreement with predicted values. The molecular structures are labelled with the 
predicted chemical shifts in ppm. The conversion of PNIPAM to A-PNIPAM was difficult to 
confirm by 1H NMR spectroscopy (Fig. 3.3.3b), where the appearance of resonances at 2.87 
and 2.94 ppm may correspond to the CH2 protons in DMF, and therefore be obscuring signals 
from the protons in ethylenediamine. 
Figure 3.3.2. Synthesis of amine functionalised PNIPAM 
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Figure 3.3.3. 1H NMR spectra of (a) PNIPAM and (b) A-PNIPAM in CDCl3. 
(a) 
(b) 
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The FT-IR peaks at 3280, 1638, and 1533 cm-1 can be assigned to the NH protons and 
the amide bond in PNIPAM (Fig. 3.3.4). The FT-IR peaks found in A-PNIPAM are almost 
identical to the peaks found in PNIPAM however the disappearance of the peak at 1055 cm-1 
suggests that the C-OH stretch of the terminal acid group has been replaced. MALDI-TOF 
mass spectrometry (Fig. 3.3.5) provided additional confirmation for the formation of 
PNIPAM, where the separation of mass peaks in a series corresponds to the molecular weight 
of the monomer NIPAM (113 Da). The average molecular weight of the synthesised polymer 
was also determined by mass spectrometry, and in Fig. 3.3.4 it can be readily seen that our 
polymer has a mass of approximately 11,000 Da.  
Confirming the conversion of PNIPAM to A-PNIPAM using the data in Fig. 3.3.4 
would, under extremely controlled sample preparation methods, be simple. As we 
demonstrated in chapter 2, it is possible to take a peak from the MALDI fingerprint for 
PNIPAM, add the mass corresponding to the addition of ethylenediamine (59.22 Da), and 
subtract the monomer weight for NIPAM (113 Da) until you arrive at a peak observed in the 
fingerprint for A-PNIPAM. However, our spectra seem to indicate that we did not obtain A-
PNIPAM. For example, if we take the peak from the PNIPAM spectrum at 11024.8 and add 
the mass corresponding to the addition of ethylenediamine (59.22), we arrive at 11084.02, 
which is not in the A-PNIPAM spectrum. Furthermore, subtracting the monomer weight for 
NIPAM gets us to 10971.02 which is also not found in the A-PNIPAM spectrum. This data, 
coupled with lack of solid NMR spectroscopy evidence suggests that we did not obtain A-
PNIPAM as our final product, regardless of having observed our product crash-out of solution 
above the LCST of 32 ˚C.  
However, Cohen and co-workers [88] demonstrated that small changes in pH and 
matrix solution composition suppressed or favoured desorption in MALDI-TOF MS. This was 
due to differences in the incorporation of the analyte molecules into the matrix crystals. In 
fact, another phenomenon described as the Marangoni effect [89] may have influenced 
hydrophilic analytes to accumulate at the periphery of the sample deposit leading to 
discrimination effects between different oligomers and poor reproducibility. Considering our 
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samples were prepared at different times, our analyte fingerprints cannot be successfully 
compared to each other.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.4. FT-IR spectra of (a) bare clusters, functionalised clusters, PNIPAM and A-
PNIPAM and (b) selected region of PNIPAM and A-PNIPAM. 
(a) 
(b) 
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Figure 3.3.5. MALDI-TOF mass spectra of PNIPAM and A-PNIPAM where the zoomed in 
regions show mass peaks of a series are separated by 113 Da. 
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With the difficulties faced in characterising our polymer, we decided to attempt to 
graft the polymer we had synthesised onto our NP clusters. We assumed that if the particles 
exhibited a phase transition at 32 ˚C then we can propose that our particles contain some 
PNIPAM. 
3.4 Functionalisation of Clusters. The amine-modified polymers (A-PNIPAM) were 
reacted with the carboxylic acid groups decorating the iron oxide clusters. This was done via 
an amidation reaction facilitated by the coupling agent COMU in DMF, following a reaction 
similar to that in Fig. 3.3.2. The reaction mixture was stirred at room temperature for 72 h 
before the particles were collected by centrifugation and re-dispersed in water. 
TEM images of the functionalised clusters (Fig. 3.2.2c) show a marked change in 
appearance, where the clusters are surrounded by a large concentration of single nanoparticles. 
This may be due to the “stickier” nature of the polymer attached to the cluster’s surface. DLS 
measurements demonstrate a ~10 nm increase in size, indicating that the polymer was 
successfully grafted onto the cluster’s surface (Table 3.4.1).  
The chemical structure and composition of the cluster surface was determined by FT-
IR. The bands corresponding to the amine of the pyrrole ring and A-PNIPAM are highlighted 
by the blue box in Fig. 3.4.1. The peaks at 1682 and 1598 cm-1 due to N-H bending can be 
associated with the secondary amide bonds in A-PNIPAM (orange box). The peak at 1146 cm-
1 due to C-N stretching in A-PNIPAM is shown in the green box. The appearance of the 
absorption bands attributed to A-PNIPAM indicates that the clusters were successfully grafted 
with the A-PNIPAM polymer. 
Additionally, thermogravimetric analysis (TGA) was performed under nitrogen to 
accurately estimate the total organic content (TOC) on the nanoparticle clusters. The data in 
Table 3.4.1 was calculated using the TGA curve shown in Fig. 3.4.2 where the average 
grafting density was calculated from the ratio of the weight loss (200 – 600 ˚C) to the total 
surface area of the clusters, assuming the average molecular weight of A-PNIPAM from Fig. 
3.3.5. A grafting density of 1.21 chains/nm2 was calculated for the PNIPAM functionalised 
clusters. In addition, the zeta potentials of the bare clusters and A-PNIPAM clusters were -
38.6 and -24.0 mV, respectively (Table 3.4.1).  These differences indicate a change has 
occurred to the bare cluster’s surface after functionalisation. However, the decrease in zeta 
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potential suggests that the A-PNIPAM clusters have a lower colloidal stability compared to 
the bare clusters, likely due to the bulky nature of the grafted polymer. 
To determine if the grafted polymer could induce a phase transition on the NP clusters 
and cause them to aggregate, we performed a DLS analysis of the clusters as a function of 
temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1. FT-IR spectra of bare clusters and clusters functionalised with A-PNIPAM. 
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Figure 3.4.2. TGA Curves for Bare (Un-functionalised) and A-PNIPAM functionalised 
Clusters. 
 
Table 3.4.1. Properties of Bare and Functionalised Clusters 
(a)Cluster size as determined by DLS measurements. (b)Weight loss (200 – 600 ˚C) and inorganic 
fraction was determined by TGA. (c)Grafting density was calculated from the average molecular weight 
of the polymer (Fig. 3.3.5), weight loss (200-600 ˚C), inorganic fraction and average cluster diameter 
[Appendix]. 
Cluster 
Size (nm)a 
Coating 
Weight Loss 
(200 – 600 ˚C) 
(wt %)b 
Inorganic 
Fraction (wt 
%)b 
Grafting 
Density 
(Chains/nm2)c 
Zeta 
Potential 
(mV)d 
91.14 ± 2.5 
Bare (i.e 
Polypyrrole) 
7.27 92.7 0.09 -38.6 
102.7 ± 0.6 A-PNIPAM 19.2 80.8 1.21 -24.0 
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3.5 Thermally Induced Aggregation. The count rate and size of the clusters vs 
temperature was monitored using DLS. The sample was allowed to equilibrate for 5 min every 
5 ˚C before three measurements were taken at a given temperature. In Fig. 3.5.1, blue line 
represents the change in hydrodynamic size as a function of temperature, and the red line 
indicates count rate. 
 
 
Figure 3.5.1. DLS data showing cluster size (blue line) and count rate (red line) vs temperature 
of (a) bare clusters and (b) A-PNIPAM clusters. Where three measurements were taken every 
5 ˚C with an equilibration time of 5 min per measurement.  
(b) 
(a) 
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The behaviour of the particles was observed from 20 to 45 ˚C by measuring the count 
rate vs. temperature in a 1 mg/mL sample of particles. The count rate provides a sensitive 
measure of aggregation and provides an indicator of the point of aggregation. Upon heating, 
the count rate of the A-PNIPAM clusters significantly decreases above the LCST of PNIPAM 
in water (32 ˚C), followed by a slight decrease in particle size (Fig. 3.5.1b). The behaviour of 
these particles goes against expected results, where aggregation would be indicated by an 
increase in count rate followed by an increase in size. The response of the bare clusters may 
provide some explanation for this behaviour (Fig. 3.5.1a). The polymer coating on the bare 
iron oxide clusters is reported to have a glass-transition temperature (Tg) of 44 ˚C, meaning 
that at this temperature the polymer phase should soften and dilate, resulting in an increase in 
observed size [39]. As seen in Fig. 3.5.1a, the count rate decrease observed at 40 ˚C is 
mirrored by a decrease in size, which correlates with expected behaviour. The competing 
effects from the LCST of PNIPAM and the Tg of the polypyrrole polymer to which the 
PNIPAM is attached, may explain why the size of the A-PNIPAM clusters seems to exhibit a 
slow and insignificant decrease. 
   Although some changes in size and count rate were observed through DLS, visual 
inspection of the solutions (Concentration: 1 mg/mL) above the LCST of PNIPAM showed no 
turbidity or precipitates. According to work done by Reimhult et al. [68], PNIPAM coated 
nanoparticles exhibited concentration dependent aggregation and precipitation, where 
concentrations of 5 mg/mL resulted in observably turbid samples. It has also been established 
that a grafting density of >2 chains/nm2 on irregularly shaped NPs is required for colloidal 
stability under high dilution and elevated temperatures [37]. Therefore, the combination of 
low grafting densities (1.21 chains/nm2), and low particle concentrations may explain the lack 
of observable aggregation above the LCST. 
 3.6 Conclusion. With some modifications to the literature synthesis we were able to 
obtain iron oxide NP clusters. Also, we managed to synthesise PNIPAM successfully and 
efficiently as discussed in section 3.3. However, modification of PNIPAM with 
ethylenediamine proved more difficult. Our product was identified by MALDI-TOF MS as a 
polymer of PNIPAM, due to its high molecular weight and a 113 Da separation of mass peaks 
in a series, however, the spectrum did not fit with that expected for A-PNIPAM. Furthermore, 
 
 
77 
we were unable to identify our polymer by other means, except that it displayed the LCST 
behaviour of PNIPAM. In an attempt to functionalise NP clusters with our PNIPAM based 
polymer we observed the appearance of several absorption bands associated with PNIPAM. 
Furthermore, TGA resulted in a 19.2 % mass loss, suggesting that our polymer had been 
successfully grafted onto the NP clusters. Observing the count rate and size of the clusters as a 
function of temperature failed to confirm if the polymer had any effect on the behaviour of the 
clusters. Furthermore, we could not rule out if the combined effects of the glass transition 
temperature of the native polypyrrole coating and the LCST of PNIPAM were the reason we 
did not observe a decrease in particle size with increasing temperature. 
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Chapter 4. Experimental 
4.1. MR Fluids for Controlling Pharmaceutical Crystal Growth 
Materials. Carbonyl iron (CI) microparticles consisting of ³97% iron particles (Sigma 
Aldrich), silicone oil 100 mPa, poly(ethylene glycol) methyl ether 5000 (mPEG), succinic 
anhydride, 4-(dimethylamino)pyridine (DMAP), triethylamine (TEA) (all from Sigma 
Aldrich), oleic acid (Scientific Laboratory Supplies), Carbamazepine (CBZ) 98% (Fisher 
Scientific). 
 Preparation of magnetic suspensions. Bare carbonyl iron (CI) microparticles were 
suspended in silicone oil (viscosity hc=100mPa), water or toluene with 40 wt.% particle 
concentrations. In the case of silicone oil, the suspensions were mechanically stirred, 
otherwise suspensions were sonicated or mixed by vortex before each measurement. 
 Synthesis of acid terminated mPEG. Dried mPEG (25 g, 5 mmol) was dissolved in 
dry THF in a two-neck round-bottomed flask. Succinic anhydride (0.60 g, 6 mmol), DMAP 
(0.73 g, 6 mmol), and TEA (0.84 mL, 6 mmol) were added to the solution and reacted at room 
temperature under a nitrogen atmosphere for 24hrs. The mixture was evaporated  
 
 
 
 
 
by rotovap to remove solvent and the residue was dissolved in 20 mL of 1M aqueous solution 
of NaHCO3, and then cooled to 0-5˚C and filtered. The filtrate was adjusted to a pH of 4 with 
6N HCl and extracted with chloroform. The obtained organic phase was washed with 
deionised water. The solution was then concentrated using a rotovap and precipitated into 
excess diethyl ether. The precipitates were filtered and dried under high vacuum to obtain a 
mass of 15.22 g (60%). 1H NMR (400 MHz, CDCl3): mPEG ∂ (ppm) = 3.35 (CH3-O), 3.62 
(O-CH2-CH2-O); acid terminated mPEG ∂ (ppm) = 2.62 (-CO-CH2-CH2-COOH), 3.63 (O-
CH2-CH2-O), 3.45 (CH3-O). ATR-FTIR: mPEG 𝜈 (cm-1) = 1056 (C-O, ether), 2930 (-CH2-); 
acid terminated mPEG 𝜈 (cm-1) = 1056 (C-O, ether), 1734 (-C=O, ester), 2930 (-CH2-). 
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MALDI-TOF MS: Mass peaks in a series separated by 44 Da (monomer weight of PEG), and 
peak values correspond to the addition of succinic anhydride (100 Da). 
Synthesis of NDA terminated mPEG. Acid terminated mPEG (0.51 g, 0.1 mmol), 
COMU (51 mg, 0.12 mmol), and DIPEA (17 μL, 0.1 mmol) were weighed in a flask and 
dissolved in 20 mL of DMF for 1 h under a nitrogen atmosphere. 6-nitrodopamine 
hydrogensulfate (89 mg, 0.3mmol) and DIPEA (34 μL, 0.2mmol) were stirred in 1 mL DMF 
and added to the above solution before being stirred at room temperature for 72 h. The 
solution was then acidified with a few drops of 2M HCl, precipitated in excess cold diethyl 
ether and collected by centrifugation. The product was dissolved in distilled water and 
dialyzed (membrane cutoff size of 1 kDa) against distilled water until the water remained clear 
(24 hr). The product was dried by rotovap to obtain a yield of 0.37 g (70%). 1H NMR (400 
MHz, CDCl3): mPEG ∂ (ppm) = 2.45 (-CO-CH2-), 2.67(-CH2-CONH), 3.39 (CH3-O), 3.47 
(NH-CH2-CH2-Ar), 3.66 (O-CH2-CH2-O), 6.77 (CH, Ar), 7.66 (CH, Ar). ATR-FTIR: 𝜈 (cm-1) 
= 1056 (C-O, ether), 1645 (-C=O, amide), 1734 (-C=O, ester), 2930 (-CH2-). MALDI-TOF 
MS: Mass peaks in a series separated by 44 Da (monomer weight of PEG), and peak values 
correspond to the addition of nitrodopamine (166 Da). 
Functionalisation of CI with Carboxylic Acid Moieties.  Bare CI powder (5g) was 
dispersed by sonication in 30 mL of ethanol and purged with nitrogen. After 20 min of 
sonication, 1 g of acid terminated moiety (Polyethylene glycol (PEG), oleic acid, carminic 
acid or 1-naphthaleneacetic acid) was added to the dispersion and sonicated for 3 h at 40˚C 
under nitrogen. The product was collected by centrifugation and re-dispersed in ethanol, 
acetone or water depending on the moiety used. This sequence was repeated six times to wash 
the particles, and then the suspension was filtered by vacuum filtration and collected after 
drying. Yields varied according to functionality: PEG-COOH-CI (3.98g, 78%), oleic acid-CI 
(4.67g, 93%), carminic acid-CI (3.40g, 68%) and 1-naphthaleneacetic acid-CI (4.40g, 88%). 
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Crystallisation of Carbamazepine in Toluene. A solution containing carbonyl iron 
(functionalised or bare) (1 g, 17.9 mmol), and carbamazepine (20 mg, 0.085 mmol) in toluene 
(1.724 mL, 16.2 mmol) was made up in a small 5 mL vial. Each sample was sonicated for 1 
min and then heated for 10 min in a 70˚C water bath. The vial was shaken vigorously for 2 sec 
and then secured between the poles of an EPR magnet by wedging a Styrofoam holder 
between the poles. The magnet was set to a field strength of 1000 G. Crystals of 
carbamazepine typically form 8-12 h after gelation of the magnetorheological fluid, therefore 
each sample is left to crystallise for 12 h. The recovery of crystals was performed by decanting 
the toluene solution into a filter by magnetically separating the CI particles. The particles were 
rinsed several times with toluene and the process was repeated to collect as many crystals as 
possible. Crystal yields ranged from 0.33 – 1.11 mg. 
Crystallisation of Carbamazepine in Water. The process was identical to 
crystallisations in toluene with one modification. The solutions contained 3 mg of 
carbamazepine because its solubility is significantly lower in water than in toluene. Crystal 
yields ranged from 0.85 – 1.93 mg.  
Characterisation. The size and shape of carbonyl iron particles was observed by SEM 
(JEOL7800F, 1-30 kV) on 200 mesh TEM grids of Formvar stabilised with carbon. 
 Hydrolysis of PEG Ligands for Characterisation of Functionalised CI. A sample 
of PEG functionalised CI (4 g) was stirred in a 50 mL alcoholic solution of sodium hydroxide 
(2.0 M, methanol/water 9/1) for 24 h at RT. The dispersion was centrifuged to separate out the 
particles, and the resulting solution was neutralised with HCl (8.3 mL, 6 M). The precipitated 
salt was filtered, and the filtrate was dried by rotovap, this step was repeated to remove all the 
salt, and the dry product was dissolved in 5 mL of D2O. qNMR spectroscopy was performed 
to quantify the PEG content. A maleic acid standard in D2O (5 mL, 0.866 mmol) was chosen 
because the signal would not obstruct the expected signal for PEG. Each NMR tube contained 
0.5 mL of maleic acid standard and 0.4 mL of sample. Integration of the 2H signal at 6.3 ppm 
for maleic acid was used as a reference for the integration of the 4H signal for PEG circ. 3.54 
ppm.  
 Maleic Acid Displacement of Carboxylic Acid Moieties for Characterisation of 
Functionalised CI.  Functionalised CI (carminic-CI or 1-napthaleneacetic acid-CI) was 
dispersed by sonication in 20 mL of ethanol. After 5 min, maleic acid (100 mg, 0.86 mmol) 
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was added to the dispersion and sonicated for 1 h at 40˚C under nitrogen. The particles and 
solution were magnetically separated, and the solution was collected and dried under rotovap. 
The product was dissolved in 5 mL of the appropriate deuterated solvent (CDCl3 for1-
naphthaleneacetic acid and D2O for carminic acid) for NMR analysis. 
4.2. Synthesis and Surface Modification of Magnetite NP Clusters 
 
Materials. Iron(III) chloride, poly(vinyl alcohol) (PVA, Mw = 31,000-50,000), 
hydrazine monohydrate and Me6Tren were purchased from Sigma-Aldrich. Pyrrole-3-
carboxylic acid was purchased from Alfa-Aesar (MA, USA). NIPAM was purchased from 
Tokyo Chemical Industry (UK).  
 Initial Cluster synthesis. A solution of PVA (10 mL, 0.94 mM) was stirred at 85˚C 
for 1 h and then cooled to RT. FeCl3 (51.9 mg, 0.32 mmol) was added to the PVA solution 
and stirred for 1 h at RT before adding pyrrole-3-carboxylic acid (31.1 mg, 0.28 mmol) and 
stirring in the dark at RT for 72 h. Finally, hydrazine monohydrate (1.07 mL, 22 mmol) was 
added and stirred for 72 h at 90˚C in the dark to yield clustered iron oxide nanoparticle 
clusters. The NPs were collected by centrifugation and re-dispersed in distilled water. This 
process was repeated three times to wash the unmodified NP clusters. 
 Modified Cluster Synthesis. A solution of PVA (10mL, 1.75mM) was stirred at 85˚C 
for 1 h and then cooled to RT. All other steps remained the same as in the initial cluster 
synthesis. 
 PNIPAM Synthesis. NIPAM (1 g, 8.8 mmol), CuBr (13 mg, 0.09 mmol), CuBr2 (2 
mg, 0.009 mmol), and 2-methyl-2-bromopropionic acid (16.7 mg, 0.1 mmol) were weighed 
into a round-bottom flask, and 9 mL of Milli-Q water and 1 mL of methanol were added. The 
flask was closed with a septum and purged with nitrogen for 20 min before being cooled in an 
ice bath.  
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In a separate flask, Tris[2-(dimethylamino)ethyl]amine (Me6Tren) (40 μL, 0.15 mmol) was 
dissolved in 1 mL of Milli-Q water, closed with a septum and purged with nitrogen for 20 
min. The ligand solution was then injected into the monomer solution. After 24 h, the flask 
was opened to air, and the polymer was isolated by heating to 50°C. The supernatant was 
disposed, and the polymer was dried. The dried product was dissolved in THF and precipitated 
in cold diethyl ether. The polymer was collected by centrifugation and dried under high 
vacuum, to yield 926 mg (93%). 1H NMR (400 MHz, CDCl3): ∂ (ppm) =1.12 (CH3-C-CH3), 
2.46 (-[CH2]-n), 3.99 (CH-Br). ATR-FTIR: 𝜈 (cm-1) = 1533, 1638, 3280 (NH, amide in 
PNIPAM). MALDI-TOF MS: Mass peaks in a series separated by 113 Da (monomer weight 
of NIPAM). 
 Synthesis of ethylenediamine-coupled PNIPAM (A-PNIPAM). Acid terminated 
PNIPAM (500 mg, 0.05 mmol), COMU (34.3 mg, 0.08 mmol), and DIPEA (34.8 μL, 0.2 
mmol) were weighed into a round bottom flask. This mixture was dissolved in 20 mL of 
DMF, purged with nitrogen and stirred at RT for 1 h. In a 5 mL round bottom flask, 
ethylenediamine (33.5 μL, 0.5 mmol), DIPEA (52.3 μL, 0.3 mmol), and 1 mL of DMF were 
added and purged with nitrogen for 20 min, before being injected into the above solution.  
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The resulting solution was stirred at RT for 72 h, after which it was acidified with a few drops 
of HCl (2 M). The polymer was precipitated by dropping the solution in cold diethyl ether and 
collected by centrifugation. The collected polymer was dissolved in water and dialyzed against 
distilled water until the water remained clear (membrane cutoff size 1 kDa). The 
ethylenediamine-coupled PNIPAM (A-PNIPAM) was collected by drying under a high 
vacuum to yield 113.5 mg (23%). Characterisations did not confirm successful conversion. 
 Functionalisation of Iron Oxide Clusters with A-PNIPAM. Iron oxide clusters (2.3 
mg, 9.94 µmol), COMU (4.26 mg, 9.94 µmol), and DIPEA (1.73 µL, 18 µmol) were weighed 
into a 10 mL round bottom flask. The mixture was dissolved in 4 mL of DMF, purged with 
nitrogen and stirred at RT for 1 h. In a 5 mL round bottom flask, A-PNIPAM (100 mg, 9.94 
µmol) and DIPEA (1 µL, 10.4 µmol) were mixed in 1 mL of DMF and purged with nitrogen 
for 20 min before being injected into the above solution. The resulting solution was stirred at 
RT for 72 h, after which the solution was exposed to air and the particles were collected by 
centrifugation and re-dispersed in water. 
 Characterisation. The size and shape of the iron oxide clusters was observed by TEM 
(JEOL 2010, 200 kV). The hydrodynamic diameters and zeta potentials were measured using 
dynamic light scattering (DLS, Malvern Zetasizer Nano ZS). The inorganic and organic 
fractions of the iron oxide clusters and functionalised iron oxide clusters were measured using 
thermogravimetry (TGA, PL Thermal Sciences STA 625). The Fourier-transform infrared 
(FTIR) spectra were collected using an ATR-FTIR instrument (Perkin Elmer Spectrum Two 
FT-IR Spectrometer). PNIPAM and A-PNIPAM polymers were characterised by ATR-FTIR, 
NMR and Matrix Assisted Laser Desorption/Ionisation-Time of Flight mass spectrometry 
(MALDI-TOF MS, Bruker UltraFlex, linear ion positive mode, 1000 shots). 
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Chapter 5. Conclusions and Future Work 
Exploiting the magnetorheological effect, we obtained a media that successfully 
crystallised an active pharmaceutical ingredient. The display of field dependent viscosity and 
high yield stress allowed for the crystallisation of carbamazepine crystals from a 
supersaturated solution in toluene. Furthermore, we demonstrated control over crystal 
morphology by attaching functionalities to the surface of the iron particles which interacted 
with solute molecules and affected crystal habit. We observed that carboxylic acid moieties 
display a high affinity for carbonyl iron particles, and hence can be used to design MR fluids 
that match a wide range of crystallisation conditions. Our study further suggests that 
hydrogen-bonding interactions between API and particle functionalities can overcome the π-π 
interactions between API molecules, this results in a crystal habit shift. Likewise, 
functionalities with no hydrogen-bonding potential allow the π-π interactions between API 
molecules to dominate and hence determine crystal habit. To date, there have been no reports 
of crystallisations in MR fluids, or other magnetic media. Therefore, the results of this study 
along with future work can contribute to our understanding of crystallisations. The hope is that 
this work can act as step towards improving pharmaceutical crystallisations. 
Although unsuccessful, our attempts to modify NP clusters with a temperature 
sensitive polymer will continue. The applications of such a material can have a significant and 
positive impact in the world of cancer therapy. 
Future Work 
 In an effort to understand the reasons behind crystal habit shifts in MR fluids, future 
work should focus on the effects of hydrogen bonding interactions between particle 
functionalities and active pharmaceutical ingredients (API). It is important to quantify the 
hydrogen bond-donating potential of the particle functionality relative to the API. Quantifying 
this would provide a variable that can be monitored and changed in order to determine its 
effect on API interactions and hence crystal habit. The effect of carbonyl iron particle size 
should also be explored, as grafting densities for these particles would vary and hence affect 
interactions between API and functionality.  
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Appendix 
 
Estimating the mass of PEG polymer required for functionalisation of carbonyl iron 
Particle Size = 2 µm 
Estimated grafting density = 2 × 10* chains/µ𝑚+	
Density of carbonyl iron	= 7.86 × 10-12g/µm3	
Volume of particle =	 43 πr3= 43 ∙π∙13	µm3	
Surface area of particle = 4πr2=4∙π∙12 µm2	
Mass of polymer = 5488	
Mass of polymer chains =
2 × 10* ∙ 4π∙5488g/mol
6.022 × 10+,  = 2.29 × 10-13g	
Mass of particle = >43 π? ∙@7.86 × 10-12A = 3.29 × 10-11g	
Mass of particle/Mass of chains=	 3.29 × 10-11g
2.29 × 10-13g
= 144 
Mass of polymer required for 1 g of carbonyl iron=	 1 g144 = 6.94 mg 
 
Calculating the grafting density of PEG on carbonyl iron from qNMR 
Particle Size = 2 µm 
Density of carbonyl iron	= 7.86 × 10-12g/µm3	
Volume of Particle =	 43 πr3= 43 ∙π∙13	µm3	
Surface Area of Particle = 4πr2=4∙π∙12 µm2	
Mass of PEG from qNMR = 0.54 ± 0.06 mg	
Number of polymer chains =
5.4 × 10-.𝑔
5486 g/mol ∙6.022 × 10+, = 5.93 × 1016	
Number of particles =	 4gC43𝜋 ∙ 7.86 × 10-12E= 1.21 × 10// 
Chains/Particle =	 5.82 × 1016
1.21 × 1011
= 4.90 × 100 
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Chains/µ𝑚+ =	 4.81 × 1004π = 3.90 × 10.  
Estimating the efficiency of functionalisation from UV-Visible Spectroscopy data 
Conc0 min = 2.13 × 10-.𝑀 
Abs0 min = 0.561 
Abs20 min = 0.316 
Conc20 min = >A20 minA0 min ? ∙Conc0 min 
Conc20 min = >0.3160.561? ∙2.13 × 10-4M=1.20 × 10-4M 
Conc20 min- Conc0 min = 9.30 × 10-4M   
Cgrafted= 9.30 ×10-4M ∙ 0.001 L ∙ 5488 g/mol = 5.1 × 10-4g 
Cgrafted=0.51 mg 
Estimated Cgrafted= 1 g/144 = 6.94 × 10-3g 
Grafting Efficiency= 
0.516.94 ∙100 = 7.3% 
 
Grafting Density Calculations for Magnetite NP Clusters 
Bare Clusters 
Cluster Size=91.14 nm 
Density of Iron Oxide	(Magnetite)=5.18×10-21g/nm3 
Mass Loss	(From TGA)=0.160032 mg 
Inorganic Fraction=2.03997 mg 
Volume of Clusters=	 43 πr3= 43 ∙π∙45.573=3.9639×105 nm3 
Surface Area of Clusters=4πr2=4∙π∙45.572=2.6096×104 nm2 
Mass of Polymer PVA=41,000 
Number of Polymer Chains=
0.160032×10-3
41,000 ∙6.022×1023=2.351×1015 
Number of Particles=
2.03997×10-3
(3.9639×105 nm3)(5.18×10-21g/nm3)
=9.94×1011 
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Chains per Particle=	 2.351×1015
9.94×1011
=2370 chains/particle 
Chains
nm2 =
2370
2.61×104
=0.091 chains/nm2 
 
A-PNIPAM Clusters 
Cluster Size=102.7 nm 
Density of Iron Oxide (Magnetite)=5.18×10-21g/nm3 
Mass Loss (From TGA)=0.3836 mg 
Inorganic Fraction=1.6164 mg 
Volume of Clusters= 
4
3 πr
3=
4
3 ∙π∙51.353=5.672×105 nm3 
Surface Area of Clusters=4πr2=4∙π∙51.352=3.314×104 nm2 
Mass of A-PNIPAM=11,058 g/mol 
Number of Polymer Chains=
0.3836×10-3
11,058 ∙6.022×1023=2.089×1016 
Number of Particles=
1.6164×10-3
(5.672×105 nm3)(5.18×10-21g/nm3)
=5.502×1011 
Chains per Particle= 
2.089×1016
5.502×1011
=37,970 chains/particle 
Chains
nm2 =
39,970
3.314×104
=1.206 chains/nm2 
 
 
 
 
 
